
  
    
      
        Background_NNP
        Celiac_NNP disease_NN (_( CD_NNP )_) is_VBZ a_DT common_NN ,_, familial_NN ,_, autoimmune_JJ
        gastrointestinal_NN disease_NN ._. It_PRP is_VBZ caused_VBN by_IN sensitivity_NN to_TO
        the_DT dietary_JJ protein_NN gluten_NN ,_, which_WDT is_VBZ present_JJ in_IN wheat_NN ,_, rye_NN
        and_CC barley_NN ._. Symptoms_NNP include_VBP growth_NN failure_NN ,_, abdominal_NN
        pain_NN ,_, and_CC diarrhea_NN ._. Dermatitis_NNP herpetiformis_NNS is_VBZ a_DT cutaneous_JJ
        manifestation_NN of_IN CD_NNP ._. Complications_NNP of_IN CD_NNP include_VBP lymphoma_NN ,_,
        osteoporosis_NNS ,_, anemia_NN ,_, and_CC seizures_NNS ._. The_DT prevalence_NN of_IN CD_NNP in_IN
        the_DT US_NNP is_VBZ 1_CD :_: 250_CD [_NN 1_CD ]_NN and_CC the_DT ratio_NN of_IN symptomatic_JJ to_TO
        asymptomatic_JJ cases_NNS is_VBZ between_IN 1_CD :_: 5_CD and_CC 1_CD :_: 7_CD [_NN 2_CD ]_NN ._. Before_IN
        the_DT advent_NN of_IN serological_JJ testing_NN for_IN diagnosing_VBG CD_NNP ,_, it_PRP was_VBD
        considered_VBN a_DT rare_JJ disease_NN in_IN the_DT US_NNP ._.
        The_DT clinical_JJ standard_NN for_IN diagnosis_NN of_IN CD_NNP is_VBZ a_DT small_JJ
        intestinal_NN biopsy_NN showing_VBG villus_JJ atrophy_NN and_CC resolution_NN of_IN
        symptoms_NNS on_IN a_DT gluten-free_JJ diet_NN ._. However_RB ,_, small_JJ intestinal_NN
        biopsy_NN is_VBZ expensive_JJ ,_, invasive_JJ ,_, and_CC often_RB rejected_VBN by_IN the_DT US_NNP
        patient_NN population_NN ._. The_DT serological_JJ IgA_NNP endomysial_NN antibody_NN
        (_( EMA_NNP )_) test_NN is_VBZ a_DT screening_NN tool_NN that_WDT has_VBZ greatly_RB facilitated_JJ
        evaluation_NN for_IN CD_NNP in_IN people_NNS with_IN suggestive_JJ symptoms_NNS and_CC in_IN
        high-risk_JJ populations_NNS ._. IgA_NNP EMA_NNP testing_NN has_VBZ proven_VBN to_TO be_VB
        greater_JJR than_IN 95_CD %_NN sensitive_JJ for_IN adults_NNS and_CC children_NNS with_IN
        classic_JJ symptomatic_JJ CD_NNP [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD ]_NN and_CC greater_JJR
        than_IN 98_CD %_NN specific_JJ in_IN controls_NNS without_IN known_VBN clinical_JJ
        disease_NN [_NN 11_CD 12_CD ]_NN ._. It_PRP is_VBZ therefore_RB an_DT inexpensive_JJ and_CC
        specific_JJ method_NN of_IN screening_VBG family_NN members_NNS for_IN genetic_JJ
        studies_NNS ._. Moreover_RB ,_, a_DT recent_JJ study_NN has_VBZ identified_VBN
        symptomatic_JJ EMA_NNP positive_JJ individuals_NNS who_WP have_VBP CD_NNP in_IN whom_WP
        intestinal_NN biopsies_NNS were_VBD normal_JJ with_IN only_RB minor_JJ mucosal_NN
        lesions_NNS ._. All_DT the_DT patients_NNS showed_VBD clinical_JJ and_CC serological_JJ
        recovery_NN on_IN a_DT gluten-free_JJ diet_NN ._. They_PRP propose_VBP that_IN
        sero-logic_JJ criteria_NNS may_MD be_VB more_RBR definitive_JJ in_IN the_DT
        diagnostic_JJ process_NN than_IN traditional_JJ biopsy_NN criteria_NNS [_NN 13_CD ]_NN
        ._.
        CD_NNP has_VBZ a_DT strong_JJ genetic_JJ association_NN with_IN the_DT HLA_NNP class_NN
        II_NNP DQ_NNP 2_CD genotype_NN composed_VBN of_IN the_DT DQA_NNP 1_CD *_NN 05_CD and_CC DQB_NNP 1_CD *_NN 02_CD alleles_NNS
        [_NN 14_CD ]_NN ._. However_RB ,_, the_DT HLA_NNP association_NN alone_RB is_VBZ insufficient_JJ
        to_TO explain_VB the_DT hereditary_JJ nature_NN of_IN the_DT disease_NN ,_, and_CC is_VBZ
        estimated_VBN to_TO explain_VB less_JJR than_IN half_PDT the_DT sibling_VBG risk_NN [_NN 15_CD
        16_CD 17_CD 18_CD ]_NN ._. There_EX appears_VBZ to_TO be_VB genetic_JJ heterogeneity_NN ,_,
        implying_VBG that_IN more_JJR than_IN one_CD additional_JJ gene_NN is_VBZ involved_VBN in_IN
        the_DT disease_NN ._. With_IN current_JJ analysis_NN software_NN ,_, it_PRP is_VBZ possible_JJ
        to_TO map_VB complex_JJ traits_NNS like_IN CD_NNP ,_, where_WRB several_JJ genetic_JJ loci_NN
        are_VBP probably_RB involved_VBN and_CC the_DT mode_NN of_IN inheritance_NN is_VBZ
        unclear_JJ ._.
        One_CD first_JJ step_NN to_TO identifying_VBG genes_NNS predisposing_VBG to_TO CD_NNP
        is_VBZ to_TO investigate_VB candidate_NN genes_NNS ._. Likely_JJ candidates_NNS
        include_VBP the_DT classes_NNS of_IN genes_NNS involved_VBN in_IN immune_JJ function_NN ,_,
        e_SYM ._. g_SYM ._. ,_, T-_NNP cell_NN receptor_NN (_( TCR_NNP )_) genes_NNS and_CC immune-modulating_JJ
        genes_NNS ._. Other_JJ candidate_NN genes_NNS are_VBP those_DT from_IN associated_VBN ,_,
        independent_JJ diseases_NNS in_IN which_WDT there_EX is_VBZ a_DT higher_JJR rate_NN of_IN CD_NNP
        than_IN in_IN the_DT general_JJ population_NN ,_, e_SYM ._. g_SYM ._. ,_, other_JJ autoimmune_JJ
        diseases_NNS such_JJ as_IN insulin_NN dependent_JJ diabetes_NN mellitus_JJ
        (_( IDDM_NNP )_) ._. These_DT associations_NNS may_MD be_VB explained_VBN by_IN common_JJ
        gene_NN (_( s_VBZ )_) responsible_JJ for_IN both_DT diseases_NNS or_CC the_DT diseases_NNS may_MD
        share_VB a_DT similar_JJ autoimmune_JJ pathogenic_JJ mechanism_NN [_NN 19_CD ]_NN ._.
        There_EX have_VBP been_VBN several_JJ European_JJ studies_NNS to_TO localize_NN genes_NNS
        for_IN CD_NNP ,_, but_CC no_DT significant_JJ evidence_NN for_IN linkage_NN has_VBZ been_VBN
        reported_VBN other_JJ than_IN at_IN HLA_NNP [_NN 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD
        ]_NN ._.
        In_IN this_DT first_JJ study_NN of_IN families_NNS with_IN CD_NNP from_IN North_NNP
        America_NNP ,_, we_PRP investigated_VBD linkage_NN to_TO several_JJ candidate_NN genes_NNS
        that_WDT could_MD play_VB a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN CD_NNP using_VBG 62_CD
        families_NNS with_IN at_IN least_JJS two_CD cases_NNS of_IN CD_NNP ._.
      
      
        Methods_NNP
        
          Ascertainment_NNP of_IN families_NNS with_IN CD_NNP
          Families_NNS with_IN at_IN least_JJS two_CD cases_NNS of_IN CD_NNP or_CC dermatitis_NNS
          herpetiformis_NNS were_VBD ascertained_JJ through_IN local_JJ
          gastroenterologists_NNS ,_, gluten_NN intolerance_NN support_NN groups_NNS ,_,
          and_CC advertising_NN at_IN local_JJ and_CC national_JJ celiac_NN disease_NN
          support_NN meetings_NNS ._. There_EX was_VBD no_DT selection_NN of_IN cases_NNS based_VBN
          on_IN sex_NN or_CC race_NN ,_, although_IN all_DT individuals_NNS were_VBD Caucasian_NNP ._.
          None_NN of_IN the_DT families_NNS appear_VBP to_TO be_VB related_VBN ._. The_DT research_NN
          study_NN was_VBD approved_VBN by_IN the_DT University_NNP of_IN Utah_NNP Health_NNP
          Sciences_NNPS Center_NNP Institutional_NNP Review_NNP Board_NNP ._. Participants_NNS
          ranged_VBD in_IN age_NN from_IN 2_CD years_NNS to_TO 100_CD +_NN years_NNS ._. Blood_NNP samples_NNS
          were_VBD collected_VBN from_IN affected_VBN individuals_NNS and_CC their_PRP$
          first-degree_JJ relatives_NNS ._. For_IN more_RBR distantly_RB related_VBN cases_NNS ,_,
          we_PRP also_RB collected_VBD blood_NN from_IN individuals_NNS that_WDT are_VBP
          connections_NNS between_IN the_DT cases_NNS ._. For_IN example_NN ,_, for_IN two_CD
          affected_VBN grandchildren_NNS (_( with_IN different_JJ parents_NNS )_) and_CC an_DT
          affected_VBN grandparent_NN ,_, we_PRP would_MD collect_VB samples_NNS from_IN the_DT
          grandchildren_NNS ,_, their_PRP$ parents_NNS ,_, and_CC the_DT grandparent_NN ._. The_DT
          breakdown_NN of_IN the_DT affected_VBN individuals_NNS is_VBZ shown_VBN in_IN Table_NNP
          1_CD ._.
        
        
          Diagnostic_NNP criteria_NNS
          Medical_JJ records_NNS were_VBD obtained_VBN to_TO confirm_VB previous_JJ
          biopsy-proven_JJ CD_NNP or_CC dermatitis_NNS herpetiformis_NNS ._. IgA_NNP EMA_NNP
          testing_NN was_VBD performed_VBN for_IN participants_NNS who_WP did_VBD not_RB have_VB a_DT
          biopsy_NN proven_VBN diagnosis_NN of_IN CD_NNP or_CC dermatitis_NNS
          herpetiformis_NNS ._. Since_IN IgA_NNP EMA_NNP is_VBZ highly_RB sensitive_JJ and_CC
          specific_JJ for_IN CD_NNP ,_, we_PRP did_VBD not_RB require_VB biopsy_NN confirmation_NN
          for_IN phenotype_NN assignment_NN ._.
          IgA_NNP EMA_NNP was_VBD measured_VBN by_IN indirect_JJ immunofluorescence_NN
          using_VBG primate_NN smooth_JJ muscle_NN (_( IMCO_NNP Diagnostics_NNPS ,_, Buffalo_NNP ,_,
          New_NNP York_NNP )_) as_IN substrate_NN [_NN 30_CD ]_NN ._. IgA_NNP EMA_NNP titers_NNS greater_JJR
          than_IN or_CC equal_JJ to_TO 1_CD :_: 5_CD were_VBD considered_VBN positive_JJ ._. Limiting_VBG
          dilution_NN was_VBD performed_VBN on_IN the_DT positive_JJ sera_NN ._.
        
        
          Genotyping_NNP at_IN short_JJ tandem_JJ repeat_NN markers_NNS
          (_( STRs_NNP )_)
          DNA_NNP was_VBD extracted_VBN from_IN lymphocytes_NNS using_VBG PureGene_NNP DNA_NNP
          isolation_NN kits_NNS (_( Gentra_NNP Systems_NNPS Inc_NNP ._. )_) ._. HLA_NNP DQA_NNP 1_CD and_CC DQB_NNP 1_CD
          genotypes_NNS were_VBD determined_VBN as_IN described_VBN in_IN Feolo_NNP et_CC al_NN ._. [_NN
          31_CD ]_NN ._. Genotyping_NNP of_IN DNA_NNP samples_NNS from_IN 175_CD affected_VBN
          individuals_NNS ,_, their_PRP$ parents_NNS ,_, and_CC any_DT connecting_VBG relatives_NNS
          from_IN 62_CD families_NNS was_VBD performed_VBN with_IN 25_CD markers_NNS at_IN 13_CD
          candidate_NN gene_NN regions_NNS and_CC 4_CD markers_NNS at_IN HLA_NNP ._. However_RB ,_, all_DT
          families_NNS were_VBD not_RB genotyped_JJ with_IN all_DT markers_NNS ,_, because_IN
          some_DT families_NNS were_VBD collected_VBN after_IN genotyping_VBG had_VBD been_VBN
          done_VBN for_IN some_DT of_IN the_DT STRs_NNP ._. The_DT candidate_NN gene_NN regions_NNS ,_,
          markers_NNS ,_, and_CC chromosomal_NN locations_NNS are_VBP listed_VBN in_IN Table_NNP 2_CD ._.
          For_IN all_DT markers_NNS ,_, amplification_NN of_IN 20_CD ng_NN genomic_JJ DNA_NNP in_IN a_DT
          total_JJ reaction_NN mix_NN of_IN 10_CD μl_NN was_VBD performed_VBN according_VBG to_TO
          standard_JJ PCR_NNP procedures_NNS ,_, with_IN minor_JJ modifications_NNS to_TO
          optimize_NN product_NN clarity_NN ._. Genotyping_NNP was_VBD performed_VBN either_CC
          using_VBG an_DT ABI_NNP 373_CD or_CC radioactively_RB using_VBG polyacrylamide_NN
          gels_NNS ._. Genotypic_NNP data_NNS were_VBD stored_VBN in_IN the_DT same_JJ database_NN as_IN
          all_DT kindred_JJ and_CC phenotype_NN information_NN ._.
        
        
          Linkage_NNP analysis_NN methods_NNS
          Analyses_NNS were_VBD performed_VBN using_VBG dominant_JJ and_CC recessive_JJ
          genetic_JJ models_NNS ,_, each_DT with_IN 2_CD liability_NN classes_NNS of_IN either_DT
          affected_VBN or_CC unknown_JJ /_NN unaffected_JJ based_VBN on_IN diagnostic_JJ
          criteria_NNS (_( Table_NNP 3_LS )_) ._. For_IN each_DT model_NN ,_, unaffected_JJ
          individuals_NNS and_CC individuals_NNS with_IN serology_NN or_CC biopsy_NN based_VBD
          diagnosis_NN were_VBD given_VBN a_DT penetrance_NN function_NN based_VBN on_IN
          disease_NN prevalence_NN ._. For_IN linkage_NN analysis_NN ,_, we_PRP used_VBD the_DT
          FASTLINK_NNP [_NN 32_CD ]_NN implementation_NN of_IN the_DT LINKAGE_NNP program_NN [_NN
          33_CD 34_CD ]_NN for_IN two-point_JJ analysis_NN ,_, and_CC the_DT GENEHUNTER_NNP
          program_NN [_NN 35_CD ]_NN for_IN both_DT parametric_JJ and_CC non-parametric_JJ
          (_( NPL_NNP )_) multi-point_JJ analyses_NNS ._. Two-point_NNP linkage_NN in_IN the_DT
          presence_NN of_IN locus_JJ heterogeneity_NN was_VBD assessed_VBN by_IN the_DT
          admixture_NN test_NN of_IN Ott_NNP ,_, using_VBG HOMOG_NNP [_NN 36_CD ]_NN ._. We_PRP used_VBD a_DT
          heterogeneity_NN LOD_NNP (_( HLOD_NNP )_) of_IN >_NN 1_CD ._. 3_CD to_TO indicate_VB nominal_JJ
          evidence_NN for_IN linkage_NN for_IN all_DT linkage_NN analyses_NNS [_NN 37_CD ]_NN
          ._.
        
      
      
        Results_NNS
        Candidate_NNP genes_NNS were_VBD selected_VBN based_VBN on_IN function_NN of_IN those_DT
        genes_NNS (_( i_NNP ._. e_SYM ._. ,_, T-_NNP cell_NN receptors_NNS ,_, 
        CTLA_NNP 4_CD ,_, and_CC 
        CD_NNP 4_LS )_) or_CC from_IN loci_NN of_IN associated_VBN
        diseases_NNS (_( i_NNP ._. e_SYM ._. ,_, IDDM_NNP )_) ._. Although_IN associated_VBN diseases_NNS were_VBD
        not_RB considered_VBN in_IN the_DT selection_NN of_IN families_NNS ,_, in_IN several_JJ
        families_NNS ,_, members_NNS had_VBD IDDM_NNP ._. In_IN one_CD family_NN ,_, a_DT CD_NNP case_NN ,_, his_PRP$
        sibling_VBG and_CC 3_CD extended_VBN relatives_NNS had_VBD IDDM_NNP ;_: in_IN a_DT second_JJ
        family_NN ,_, the_DT CD_NNP case_NN had_VBD IDDM_NNP ;_: in_IN a_DT third_JJ family_NN ,_, the_DT
        mother_NN ,_, 2_CD siblings_NNS ,_, a_DT daughter_NN ,_, and_CC a_DT cousin_NN of_IN a_DT CD_NNP case_NN
        had_VBD IDDM_NNP ;_: and_CC in_IN a_DT fourth_JJ family_NN ,_, the_DT sister_NN of_IN a_DT CD_NNP case_NN
        had_VBD IDDM_NNP ._.
        The_DT highest_JJS 2_CD -_: point_NN HLOD_NNP scores_NNS obtained_VBN with_IN either_DT
        model_NN are_VBP shown_VBN in_IN Table_NNP 3_CD ._. The_DT multipoint_NN HLODs_NNP were_VBD
        obtained_VBN using_VBG the_DT same_JJ model_NN as_IN the_DT 2_CD -_: point_NN HLOD_NNP shown_VBN ._.
        The_DT largest_JJS two-point_JJ and_CC multi-point_JJ LOD_NNP scores_NNS were_VBD
        obtained_VBN in_IN the_DT HLA_NNP region_NN ._. Under_IN the_DT dominant_JJ model_NN ,_, the_DT
        two-point_JJ HLOD_NNP was_VBD 3_CD ._. 1_CD (_( α_NN =_SYM 1_CD ._. 0_CD )_) at_IN D_NNP 6_CD S_NNP 426_CD (_( position_NN 60_CD ._. 4_LS
        cM_NN )_) ,_, the_DT multi-point_JJ HLOD_NNP was_VBD 5_CD ._. 02_CD (_( α_NN =_SYM 0_CD ._. 66_CD )_) (_( position_NN
        54_CD ._. 6_CD cM_NN )_) ,_, and_CC the_DT NPL_NNP was_VBD 4_CD ._. 38_CD (_( p_NN <_NN ._. 0001_CD )_) (_( position_NN
        50_CD ._. 2_LS cM_NN )_) ._. The_DT estimate_NN for_IN the_DT proportion_NN of_IN families_NNS linked_VBN
        was_VBD 0_CD ._. 66_CD for_IN the_DT multipoint_NN HLOD_NNP ,_, suggesting_VBG that_IN
        approximately_RB half_NN of_IN the_DT families_NNS are_VBP linked_VBN to_TO an_DT HLA_NNP
        susceptibility_NN locus_JJ for_IN CD_NNP ._. Of_IN the_DT 13_CD candidate_NN gene_NN
        regions_NNS investigated_VBN ,_, none_NN of_IN the_DT regions_NNS had_VBD even_RB nominal_JJ
        evidence_NN for_IN linkage_NN (_( HLOD_NNP >_NN 1_CD ._. 3_LS )_) or_CC an_DT NPL_NNP score_NN with_IN p_NN
        <_NN 0_CD ._. 05_CD ._.
      
      
        Discussion_NNP
        In_IN this_DT study_NN ,_, we_PRP examined_VBD linkage_NN to_TO a_DT set_NN of_IN candidate_NN
        genes_NNS for_IN CD_NNP ._. This_DT subset_NN of_IN genes_NNS was_VBD selected_VBN based_VBN on_IN
        genes_NNS that_WDT could_MD be_VB related_VBN to_TO CD_NNP through_IN function_NN or_CC an_DT
        associated_VBN disease_NN ._. For_IN statistical_JJ and_CC linkage_NN analysis_NN of_IN
        complex_JJ diseases_NNS ,_, we_PRP used_VBD general_JJ recessive_JJ and_CC dominant_JJ
        models_NNS ._. Several_JJ biostatisticians_NNS have_VBP suggested_VBN that_IN
        general_JJ models_NNS provide_VBP power_NN to_TO distinguish_VB linkage_NN signals_NNS
        independent_JJ of_IN the_DT true_JJ underlying_VBG disease_NN mode_NN of_IN
        inheritance_NN ,_, provided_VBD both_DT dominant_JJ and_CC recessive_JJ models_NNS
        are_VBP used_VBN [_NN 38_CD 39_CD 40_CD ]_NN ._. As_IN expected_VBN ,_, the_DT highest_JJS two-point_JJ
        and_CC multipoint_NN LOD_NNP scores_NNS were_VBD obtained_VBN in_IN the_DT HLA_NNP region_NN ,_,
        with_IN a_DT two-point_JJ HLOD_NNP of_IN 3_CD ._. 1_CD and_CC a_DT multipoint_NN HLOD_NNP of_IN 5_CD ._. 0_CD ._.
        This_DT result_NN replicates_NNS the_DT known_VBN association_NN and_CC linkage_NN of_IN
        HLA_NNP to_TO CD_NNP [_NN 22_CD 25_CD 29_CD ]_NN and_CC demonstrates_VBZ the_DT power_NN of_IN the_DT
        family_NN resource_NN to_TO detect_VB linkage_NN in_IN the_DT set_NN of_IN candidate_NN
        gene_NN markers_NNS ._.
        We_PRP were_VBD interested_JJ in_IN identifying_VBG non-_NN HLA_NNP loci_NN for_IN
        celiac_NN disease_NN ._. We_PRP were_VBD unable_JJ to_TO detect_VB even_RB nominal_JJ
        evidence_NN for_IN linkage_NN at_IN any_DT of_IN the_DT loci_NN investigated_VBN ._. For_IN
        those_DT regions_NNS where_WRB we_PRP examined_VBD only_RB 1_CD marker_NN ,_, it_PRP may_MD be_VB
        that_IN one_CD marker_NN was_VBD insufficient_JJ in_IN order_NN to_TO detect_VB linkage_NN
        even_RB if_IN it_PRP existed_VBD ._. A_DT number_NN of_IN candidate_NN genes_NNS
        investigated_VBN in_IN this_DT study_NN were_VBD examined_VBN previously_RB in_IN
        European_JJ populations_NNS ._. Our_PRP$ results_NNS are_VBP in_IN agreement_NN with_IN
        previous_JJ linkage_NN and_CC /_NN or_CC association_NN studies_NNS of_IN CD_NNP and_CC
        T-_NNP cell_NN receptor_NN genes_NNS (_( TCRα_NNP ,_, TCRγ_NNP ,_, TCRβ_NNP ,_, and_CC TCRδ_NNP )_) ,_, where_WRB
        they_PRP saw_VBD no_DT evidence_NN for_IN linkage_NN or_CC association_NN ,_, although_IN
        sample_NN sizes_NNS were_VBD small_JJ [_NN 28_CD 41_CD ]_NN ._. 
        CD_NNP 28_CD and_CC 
        CTLA-_NNP 4_CD ,_, two_CD genes_NNS encoding_VBG receptors_NNS
        that_WDT regulate_VB T-_NNP lymphocyte_NN activation_NN ,_, are_VBP located_VBN at_IN 2_CD q_NN 33_CD ._.
        Holopainen_NNP et_CC al_NN [_NN 24_CD ]_NN reported_VBD linkage_NN and_CC association_NN to_TO
        this_DT region_NN in_IN a_DT study_NN of_IN 100_CD Finnish_JJ families_NNS with_IN CD_NNP ,_,
        which_WDT may_MD suggest_VB a_DT possible_JJ founder_NN effect_NN in_IN these_DT
        families_NNS ._. In_IN a_DT case-control_JJ study_NN ,_, the_DT 
        CTLA-_NNP 4_CD polymorphism_NN ,_, 49_CD A_DT >_NN G_NNP ,_, was_VBD
        significantly_RB associated_VBN with_IN CD_NNP [_NN p_NN =_SYM 0_CD ._. 002_CD with_IN an_DT odds_NNS
        ratio_NN of_IN 2_CD ._. 36_CD (_( 95_CD %_NN confidence_NN interval_NN 1_CD ._. 37_CD -_: 4_CD ._. 06_CD )_) ]_NN [_NN 21_CD ]_NN ._.
        We_PRP did_VBD not_RB find_VB evidence_NN for_IN linkage_NN with_IN the_DT 
        CTLA-_NNP 4_CD polymorphism_NN ._.
        Genomic_NNP searches_NNS for_IN CD_NNP have_VBP been_VBN conducted_VBN in_IN several_JJ
        European_JJ populations_NNS ._. In_IN 1996_CD ,_, Zhong_NNP et_CC al_NN ._. [_NN 29_CD ]_NN studied_VBD
        40_CD affected_VBN sib_NN pairs_NNS from_IN 11_CD families_NNS ,_, and_CC reported_VBD
        significant_JJ linkage_NN at_IN 6_CD p_NN 23_CD and_CC weak_JJ evidence_NN at_IN 11_CD p_NN 11_CD ,_,
        7_CD q_NN 31_CD ._. 3_LS ,_, 22_CD cen_NN ,_, 15_CD q_NN 26_CD ,_, 5_CD q_NN 33_CD ._. 3_LS ,_, 19_CD p_NN 13_CD ._. 1_LS and_CC 19_CD q_NN 13_CD ._. 2_LS ._. Houlston_NNP
        et_CC al_NN [_NN 42_CD ]_NN ,_, studying_VBG 28_CD families_NNS ,_, found_VBD significant_JJ
        evidence_NN for_IN linkage_NN to_TO HLA_NNP ,_, but_CC no_DT evidence_NN for_IN linkage_NN to_TO
        the_DT regions_NNS suggested_VBN by_IN Zhong_NNP ,_, except_IN at_IN 15_CD q_NN 26_CD ,_, where_WRB 
        IDDM_NNP 3_CD is_VBZ localized_VBN ._. Greco_NNP et_CC al_NN ._.
        conducted_VBD a_DT genome-wide_JJ search_NN with_IN 39_CD sib_NN pairs_NNS ,_, and_CC an_DT
        additional_JJ 71_CD pairs_NNS in_IN regions_NNS of_IN interest_NN [_NN 22_CD ]_NN ._. They_PRP
        found_VBD significant_JJ evidence_NN for_IN linkage_NN at_IN HLA_NNP and_CC nominal_JJ
        evidence_NN for_IN linkage_NN on_IN 5_CD qter_NN and_CC 11_CD qter_NN ._. Using_VBG an_DT
        independent_JJ set_NN of_IN 89_CD sibpairs_NNS ,_, they_PRP reported_VBD additional_JJ
        linkage_NN evidence_NN at_IN 5_CD q_NN [_NN 23_CD ]_NN ._. King_NNP et_CC al_NN ._. [_NN 26_CD ]_NN
        performed_VBD a_DT genome-wide_JJ search_NN with_IN 16_CD CD_NNP families_NNS and_CC
        reported_VBD nominal_JJ evidence_NN for_IN linkage_NN at_IN 10_CD q_NN 23_CD ._. 1_LS and_CC
        16_CD q_NN 23_CD ._. 3_LS ._. In_IN a_DT follow-up_JJ study_NN with_IN 50_CD families_NNS ,_, King_NNP et_CC al_NN ._.
        [_NN 27_CD ]_NN reported_VBD heterogeneity_NN LOD_NNP scores_NNS >_NN 2_CD ._. 0_CD at_IN 5_CD
        regions_NNS ,_, including_VBG 11_CD p_NN 11_CD previously_RB reported_VBN by_IN Zhong_NNP et_CC
        al_NN ._. [_NN 29_CD ]_NN ._. From_IN these_DT studies_NNS ,_, the_DT only_JJ region_NN with_IN at_IN
        least_JJS nominal_JJ evidence_NN for_IN linkage_NN ,_, which_WDT overlapped_JJ with_IN
        the_DT candidate_NN regions_NNS studied_VBN here_RB ,_, was_VBD at_IN 
        IDDM_NNP 3_CD at_IN 15_CD q_NN 26_CD ._. One_CD study_NN reported_VBD
        possible_JJ evidence_NN for_IN linkage_NN [_NN 29_CD ]_NN ,_, one_CD reported_VBD weak_JJ
        evidence_NN [_NN 42_CD ]_NN ,_, and_CC two_CD reported_VBD no_DT linkage_NN [_NN 20_CD 22_CD ]_NN ._.
        We_PRP were_VBD unable_JJ to_TO detect_VB linkage_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ significant_JJ evidence_NN of_IN linkage_NN to_TO HLA_NNP replicates_NNS
        the_DT known_VBN linkage_NN and_CC association_NN of_IN HLA_NNP with_IN CD_NNP ._. In_IN our_PRP$
        families_NNS ,_, likely_JJ candidate_NN genes_NNS /_NN loci_NN did_VBD not_RB explain_VB the_DT
        susceptibility_NN to_TO CD_NNP ._. It_PRP may_MD be_VB that_IN these_DT genes_NNS /_NN loci_NN are_VBP
        not_RB involved_VBN in_IN CD_NNP ,_, that_IN we_PRP had_VBD insufficient_JJ genotyping_VBG
        within_IN regions_NNS ,_, or_CC that_IN one_CD ,_, or_CC a_DT number_NN of_IN these_DT genes_NNS ,_,
        has_VBZ a_DT small_JJ effect_NN so_IN that_IN we_PRP were_VBD unable_JJ to_TO detect_VB linkage_NN
        with_IN our_PRP$ set_NN of_IN families_NNS ._. We_PRP were_VBD unable_JJ to_TO detect_VB linkage_NN
        at_IN 
        IDDM_NNP 3_CD and_CC at_IN 
        CTLA_NNP 4_CD ,_, for_IN which_WDT positive_JJ linkages_NNS
        were_VBD previously_RB reported_VBN ._. This_DT is_VBZ similar_JJ to_TO the_DT experience_NN
        in_IN most_JJS other_JJ reported_VBD studies_NNS of_IN celiac_NN disease_NN ._.
        Non-replication_NNP of_IN linkage_NN results_NNS in_IN complex_JJ diseases_NNS is_VBZ
        common_JJ ,_, and_CC may_MD be_VB due_JJ to_TO the_DT low_JJ power_NN of_IN studies_NNS to_TO
        detect_VB genes_NNS of_IN relatively_RB small_JJ effect_NN and_CC /_NN or_CC to_TO a_DT high_JJ
        degree_NN of_IN genetic_JJ heterogeneity_NN among_IN families_NNS ._. Larger_NNP data_NNS
        sets_NNS with_IN more_JJR power_NN likely_JJ are_VBP needed_VBN in_IN order_NN to_TO find_VB
        strong_JJ evidence_NN for_IN linkage_NN ._.
      
      
        Abbreviations_NNP
        CD_NNP ,_, celiac_NN disease_NN ;_: HLOD_NNP ,_, Heterogeneity_NNP LOD_NNP :_: NPL_NNP ,_,
        non-parametric_JJ linkage_NN ;_: TCR_NNP ,_, T_NN cell_NN receptor_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
